JPH09502993A - 免疫または炎症応答の調節による抗がん遺伝子療法 - Google Patents
免疫または炎症応答の調節による抗がん遺伝子療法Info
- Publication number
- JPH09502993A JPH09502993A JP7510150A JP51015095A JPH09502993A JP H09502993 A JPH09502993 A JP H09502993A JP 7510150 A JP7510150 A JP 7510150A JP 51015095 A JP51015095 A JP 51015095A JP H09502993 A JPH09502993 A JP H09502993A
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- virus
- vector according
- viral
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2033—IL-5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 哺乳動物におけるがん治療用医薬品の製造に関する、細胞表面共刺激分 子、ケモカイン、リンパ球表面マーカーに対するモノクローナル抗体、感染性生 物(細菌、ウイルスまたは寄生虫)に特徴的なスーパー抗原、およびアジュバン ト機能を有するポリペプチドから選択される、免疫および/または炎症応答を調 節する物質の全部または一部についてコードする1以上の遺伝子を含んだDNA 断片がゲノム中に挿入されたウイルスベクターの使用。 2. 医薬品が非経口投与、特に静脈内または筋肉内投与用である、請求項1 に記載のウイルスベクターの使用。 3. 細胞表面共刺激分子が主要組織適合性遺伝子複合体(MHC)のクラス IおよびII抗原、マーカーCD27、CD28、CD30およびCD40に関す るリガンド、リンパ球機能抗原タイプ1(LFA‐1)と、細胞間付着分子タイ プ1(ICAM‐1)から選択される、請求項1または2に記載のウイルスベク ターの使用。 4. ケモカインがPF‐4(血小板因子‐4)、RANTESおよびACT ‐2から選択される、請求項1または2に記載のウイルスベクターの使用。 5. モノクローナル抗体が抗CD2、抗CD3、抗CD28および抗CD4 0モノクローナル抗体から選択される、請求項1または2に記載のウイルスベク ターの使用。 6. 哺乳動物におけるがん治療用医薬品の製造に関する、少くとも1つのサ イトカインについてコードする1以上の遺伝子を含んだDNA断片がゲノム中に 挿入され、上記医薬品が非経口投与、特に静脈内または筋肉内投与用である、ウ イルスベクターの使用。 7. サイトカインがインターロイキン、インターフェロン、コロニー刺激因 子(CSF)、腫瘍壊死因子(TNF)、マクロファージ遊走阻止因子(MIF )および補体断片C5aから選択される、請求項6に記載のウイルスベクターの 使用。 8. サイトカインがインターロイキン‐2、‐4、‐5、‐6および‐7、 ガンマインターフェロン、顆粒球‐マクロファージタイプコロニー剌激因子(G M‐CSF)並びに腫瘍壊死因子タイプβ(TNFβ)から選択される、請求項 7に記載のウイルスベクターの使用。 9. ヒトにおけるがん治療用医薬品の製造に関する、請求項1〜8のいずれ か一項に記載のウイルスベクターの使用。 10. 哺乳動物における固形がん腫瘍の治療用医薬品の製造に関する、請求 項1〜9のいずれか一項に記載のウイルスベクターの使用。 11. ウイルスベクターがポックスウイルス、アデノウイルス、レトロウイ ルスおよびヘルペスウイルスから選択されるウイルスに由来する、請求項1〜1 0のいずれか一項に記載のウイルスベクターの使用。 12. ウイルスベクターが非組込み性ベクターである、請求項1〜11のい ずれか一項に記載のウイルスベクターの使用。 13. ウイルスベクターが非複製性ベクターである、請求項1〜12のいず れか一項に記載のウイルスベクターの使用。 14. ウイルスベクターがポックスウイルスに由来する、請求項11に記載 のウイルスベクターの使用。 15. ウイルスベクターがトリポックスウイルスに由来する、請求項14に 記載のウイルスベクターの使用。 16. ウイルスベクターがワクシニアウイルスに由来する、請求項14に記 載のウイルスベクターの使用。 17. ウイルスベクターが腫瘍特異性抗原についてコードする遺伝子を更に 含んでなるものである、請求項1〜16のいずれか一項に記載のウイルスベクタ ーの使用。 18. 発現に必要な要素の制御下に置かれた、がん細胞の破壊に関与する少 くとも1つの物質についてコードする1以上の遺伝子を含むDNA断片がゲノム 中に挿入され、前記物質が特異的にがん腫瘍に送達される、がん細胞に正の親和 性を示すウイルスベクターの使用。 19. 発現に必要な要素の制御下に置かれた、免疫および/または炎症応答 を調節する物質についてコードする1以上の遺伝子を含むDNA断片がゲノム中 に挿入され、免疫および/または炎症応答を調節する前記物質ががん腫瘍に特異 的に送達される、請求項18に記載のウイルスベクターの使用。 20. ウイルスベクターがポックスウイルスに由来する、請求項18または 19に記載のウイルスベクターの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9311601A FR2710536B1 (fr) | 1993-09-29 | 1993-09-29 | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
FR93/11601 | 1993-09-29 | ||
PCT/FR1994/001133 WO1995009241A2 (fr) | 1993-09-29 | 1994-09-28 | Therapie genique anticancereuse par modulation de la reponse immunitaire et/ou inflammatoire |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502993A true JPH09502993A (ja) | 1997-03-25 |
JP4094053B2 JP4094053B2 (ja) | 2008-06-04 |
Family
ID=9451366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51015095A Expired - Lifetime JP4094053B2 (ja) | 1993-09-29 | 1994-09-28 | 免疫または炎症応答の調節による抗がん遺伝子療法 |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1156119B9 (ja) |
JP (1) | JP4094053B2 (ja) |
AT (2) | ATE247714T1 (ja) |
AU (1) | AU709336C (ja) |
DE (2) | DE69434708T2 (ja) |
DK (2) | DK0721510T3 (ja) |
ES (2) | ES2260117T3 (ja) |
FR (1) | FR2710536B1 (ja) |
HK (1) | HK1042728B (ja) |
PT (2) | PT721510E (ja) |
SG (1) | SG96534A1 (ja) |
WO (1) | WO1995009241A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005523875A (ja) * | 2002-07-31 | 2005-08-11 | ゲネルクス コーポレーション | 腫瘍の診断および治療のための微生物および細胞 |
JP2009507853A (ja) * | 2005-09-07 | 2009-02-26 | ジェンネレックス インコーポレイティッド | Gm−csf発現ポックスウイルスを用いる転移性および/または全身播種性癌の全身処置 |
US9005602B2 (en) | 2006-10-16 | 2015-04-14 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
US9492534B2 (en) | 2003-06-18 | 2016-11-15 | Genelux Corporation | Microorganisms for therapy |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US6093700A (en) | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
CA2190290C (en) * | 1994-05-13 | 2011-07-05 | Michael J. Mastrangelo | A method of inducing an immune response using vaccinia virus recombinants |
US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
US6165460A (en) * | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
GB2324960A (en) * | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
JP4472866B2 (ja) | 1997-11-06 | 2010-06-02 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ナイセリア抗原 |
DE69941567D1 (de) | 1998-01-14 | 2009-12-03 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
CN100379757C (zh) | 1998-05-01 | 2008-04-09 | 希龙公司 | 脑膜炎奈瑟球菌抗原和组合物 |
JP2003518363A (ja) | 1999-04-30 | 2003-06-10 | カイロン エセ.ピー.アー. | 保存されたナイセリア抗原 |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
PT2275551E (pt) | 1999-10-29 | 2015-06-29 | Novartis Vaccines & Diagnostic | Péptidos antigénicos de neisseria |
AU784518B2 (en) | 2000-01-17 | 2006-04-27 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
JP2005501512A (ja) * | 2001-01-26 | 2005-01-20 | トランジェーヌ、ソシエテ、アノニム | 哺乳動物の治療を目的とする医薬組成物の製造のための生物材料 |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
ES2386386T3 (es) | 2001-12-12 | 2012-08-20 | Novartis Vaccines And Diagnostics S.R.L. | Inmunización contra Chlamydia trachomatis |
EP1369491A1 (en) | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
CA2561696C (en) | 2004-03-29 | 2013-09-03 | Galpharma Co., Ltd. | Novel modified galectin 9 proteins and use thereof |
RU2313349C2 (ru) * | 2006-01-16 | 2007-12-27 | Михаил Аркадьевич Шурдов | Способ лечения онкологических заболеваний |
PT2054431E (pt) | 2006-06-09 | 2011-11-03 | Novartis Ag | Confórmeros de adesinas bacterianas |
US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
SG178090A1 (en) | 2009-07-21 | 2012-03-29 | Transgene Sa | Enzymatic composition for the digestion of chicken embryos |
TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
RU2704485C2 (ru) | 2014-12-01 | 2019-10-29 | Трансген Са | Стабильные жидкие препараты вируса осповакцины |
JP7406377B2 (ja) | 2017-05-15 | 2023-12-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定なウイルス含有組成物 |
WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2583429B1 (fr) * | 1985-06-18 | 1989-11-03 | Transgene Sa | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u |
FR2583770B1 (fr) * | 1985-06-21 | 1988-08-19 | Transgene Sa | Expression de l'il-2 humaine dans les cellules de mammiferes par un poxvirus recombine |
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
CA2120503C (en) * | 1991-10-04 | 2006-04-04 | Glenn Dranoff | The regulation of systemic immune responses utilizing cytokines and antigens |
DK0668781T3 (da) * | 1991-10-25 | 2000-04-17 | Sidney Kimmel Cancer Ct | Lymfokingenterapi af cancer i kombination med tumorantigener |
US5314813A (en) * | 1992-02-19 | 1994-05-24 | Scripps Research Institute | Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines |
FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
WO1994004196A1 (en) * | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
-
1993
- 1993-09-29 FR FR9311601A patent/FR2710536B1/fr not_active Expired - Fee Related
-
1994
- 1994-09-28 EP EP01110326A patent/EP1156119B9/fr not_active Expired - Lifetime
- 1994-09-28 DK DK94928924T patent/DK0721510T3/da active
- 1994-09-28 AT AT94928924T patent/ATE247714T1/de active
- 1994-09-28 PT PT94928924T patent/PT721510E/pt unknown
- 1994-09-28 ES ES01110326T patent/ES2260117T3/es not_active Expired - Lifetime
- 1994-09-28 ES ES94928924T patent/ES2204922T3/es not_active Expired - Lifetime
- 1994-09-28 AU AU78159/94A patent/AU709336C/en not_active Expired
- 1994-09-28 DK DK01110326T patent/DK1156119T3/da active
- 1994-09-28 DE DE69434708T patent/DE69434708T2/de not_active Expired - Lifetime
- 1994-09-28 WO PCT/FR1994/001133 patent/WO1995009241A2/fr active IP Right Grant
- 1994-09-28 AT AT01110326T patent/ATE323774T1/de active
- 1994-09-28 EP EP94928924A patent/EP0721510B1/fr not_active Expired - Lifetime
- 1994-09-28 SG SG9608019A patent/SG96534A1/en unknown
- 1994-09-28 DE DE69433060T patent/DE69433060T2/de not_active Expired - Lifetime
- 1994-09-28 PT PT01110326T patent/PT1156119E/pt unknown
- 1994-09-28 JP JP51015095A patent/JP4094053B2/ja not_active Expired - Lifetime
-
2002
- 2002-05-21 HK HK02103801.1A patent/HK1042728B/zh not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005523875A (ja) * | 2002-07-31 | 2005-08-11 | ゲネルクス コーポレーション | 腫瘍の診断および治療のための微生物および細胞 |
JP4634710B2 (ja) * | 2002-07-31 | 2011-02-16 | ゲネルクス コーポレーション | 腫瘍の診断および治療のための微生物および細胞 |
US9492534B2 (en) | 2003-06-18 | 2016-11-15 | Genelux Corporation | Microorganisms for therapy |
US10463730B2 (en) | 2003-06-18 | 2019-11-05 | Genelux Corporation | Microorganisms for therapy |
JP2009507853A (ja) * | 2005-09-07 | 2009-02-26 | ジェンネレックス インコーポレイティッド | Gm−csf発現ポックスウイルスを用いる転移性および/または全身播種性癌の全身処置 |
JP2013189456A (ja) * | 2005-09-07 | 2013-09-26 | Jennerex Inc | Gm−csf発現ポックスウイルスを用いる転移性および/または全身播種性癌の全身処置 |
US9005602B2 (en) | 2006-10-16 | 2015-04-14 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
US9944903B2 (en) | 2006-10-16 | 2018-04-17 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
Also Published As
Publication number | Publication date |
---|---|
DE69434708T2 (de) | 2007-04-05 |
EP0721510B1 (fr) | 2003-08-20 |
FR2710536B1 (fr) | 1995-12-22 |
AU709336C (en) | 2002-06-13 |
AU7815994A (en) | 1995-04-18 |
HK1042728A1 (en) | 2002-08-23 |
DE69434708D1 (de) | 2006-05-24 |
AU709336B2 (en) | 1999-08-26 |
EP1156119A3 (fr) | 2002-10-23 |
DK0721510T3 (da) | 2003-11-17 |
DE69433060D1 (de) | 2003-09-25 |
WO1995009241A3 (fr) | 1995-06-22 |
EP1156119B1 (fr) | 2006-04-19 |
ES2204922T3 (es) | 2004-05-01 |
ES2260117T3 (es) | 2006-11-01 |
ATE323774T1 (de) | 2006-05-15 |
JP4094053B2 (ja) | 2008-06-04 |
EP1156119A2 (fr) | 2001-11-21 |
SG96534A1 (en) | 2003-06-16 |
HK1042728B (zh) | 2006-11-24 |
FR2710536A1 (fr) | 1995-04-07 |
PT721510E (pt) | 2003-11-28 |
DE69433060T2 (de) | 2004-06-03 |
DK1156119T3 (da) | 2006-06-06 |
ATE247714T1 (de) | 2003-09-15 |
WO1995009241A2 (fr) | 1995-04-06 |
EP0721510A1 (fr) | 1996-07-17 |
EP1156119B9 (fr) | 2006-08-30 |
PT1156119E (pt) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4094053B2 (ja) | 免疫または炎症応答の調節による抗がん遺伝子療法 | |
KR100392984B1 (ko) | 유전자치료를위한단구-마크로파아지세포계로부터의재조합세포 | |
AU672195B2 (en) | Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment | |
CA2087525C (en) | Adoptive immunotherapy with interleukin-7 | |
EP0668781B1 (en) | Lymphokine gene therapy of cancer in combination with tumor antigens | |
JP2021526842A (ja) | I型インターフェロン及びcd40−配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療 | |
CN115552019A (zh) | 在髓样细胞和小胶质细胞中特异性表达治疗性蛋白的病毒载体 | |
US11795203B2 (en) | Protein heterodimer and use thereof | |
JPH09512165A (ja) | インターロイキン15 | |
Dorigo et al. | Gene therapy for ovarian cancer: development of novel treatment strategies | |
AU717974B2 (en) | Transduced human hematopoietic stem cells | |
Qian et al. | Gene therapy of cancer: induction of anti-tumor immunity | |
JP2002506980A (ja) | 新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法 | |
CN100435849C (zh) | 一种含白细胞介素23基因的抗肿瘤剂 | |
Kametaka et al. | Reduction of CTLL‐2 cytotoxicity by induction of apoptosis with a Fas‐estrogen receptor chimera | |
CN115605586A (zh) | 工程化溶瘤腺病毒 | |
Ackermann et al. | Transgenic IL-2 expression in Ewing tumor cell lines after transfection with Starburst dendrimers and cationic liposomes | |
Fiehn et al. | Bone marrow-derived cells as carriers of recombinant immunomodulatory cytokine genes to lymphoid organs | |
CN116334140A (zh) | 一种删除a44l基因的重组溶瘤痘苗病毒载体的构建方法及应用 | |
JP3689111B2 (ja) | インターロイキン15 | |
CA2245180A1 (en) | Transduced human hematopoietic stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050418 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070403 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070703 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080305 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110314 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110314 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120314 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120314 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130314 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140314 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |